Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy

• Verfasst von: O'Brien, Mary [VerfasserIn]
• Verfasst von: Schmid-Bindert, Gerald [VerfasserIn]
• Titel: Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy
• Titelzusatz: a double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064)
• Verf.angabe: Mary E.R. O’Brien, Rabab Gaafar, Baktiar Hasan, Jessica Menis, Tanja Cufer, Sanjay Popat, Penella J. Woll, Veerle Surmont, Vassilis Georgoulias, Ana Montes, Fiona Blackhall, Ivo Hennig, Gerald Schmid-Bindert, Paul Baas, on behalf of the EORTC-LCG
• E-Jahr: 2015
• Jahr: August 2015
• Umfang: 18 S.
• Fussnoten: Gesehen am 11.12.2018 ; Available online 11 June 2015
• Titel Quelle: Enthalten in: European journal of cancer
• Ort Quelle: Amsterdam [u.a.] : Elsevier, 1992
• Jahr Quelle: 2015
• Band/Heft Quelle: 51(2015), 12, Seite 1511-1528
• ISSN Quelle: 1879-0852
• DOI: doi:10.1016/j.ejca.2015.04.026
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Advanced
• Sach-SW: Double blind
• Sach-SW: Maintenance
• Sach-SW: NSCLC
• Sach-SW: Pazopanib
• Sach-SW: Phase III
• K10plus-PPN: 1585059358

Abstract

Background: Switch maintenance is an effective strategy in the treatment of advanced Non-Small Cell Lung Cancer (NSCLC). Pazopanib is an oral, multi-targeted tyrosine kinase inhibitor (TKI). EORTC 08092 evaluated pazopanib given as maintenance treatment following standard first line platinum-based chemotherapy in patients with advanced NSCLC. Methods: Patients with non-progressive disease after 4-6 cycles of chemotherapy were randomised to receive either pazopanib 800mg/day or matched placebo until progression or unacceptable toxicity. The primary end-point was overall survival and secondary end-points were progression-free survival (PFS) and safety. Results: A total of 600 patients were planned to be randomised. The trial was prematurely stopped following an early interim analysis, after 102 patients were randomised to pazopanib (n=50) or placebo (n=52). Median age was 64years in both arms. Median overall survival was 17.4months for pazopanib and 12.3months for placebo (adjusted hazard ratio (HR) 0.72 [95% confidence interval (CI) 0.40-1.28]; p=0.257). Median PFS was 4.3months versus 3.2months (HR 0.67, [95% CI 0.43-1.03], p=0.068). PFS rates at 4months were 56% and 45% respectively. The majority of treatment-related adverse events (AEs) were grade 1-2. Grade 3-4 AEs (pazopanib versus placebo) were hypertension (38% versus 8%), neutropenia (8% versus 0%), and elevated SGPT (6% versus 0%). Of the patients randomised to pazopanib, 22% withdrew due to a treatment-related AE. Conclusions: Switch maintenance with pazopanib following platinum-based chemotherapy in advanced NSCLC patients had limited side-effects. This study was stopped due to lack of efficacy by stringent criteria for PFS at a futility interim analysis.